反应详情

温度

100 °C

Prepared according to Example 131, (S)-3-amino-1-Boc-piperidine (180 μL, 0.759 mmol, CNH Technologies, Inc., Woburn, Mass.), 2-(3-fluoro-2-methylquinoxalin-5-yl)-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-one (Example 126; 75 mg, 0.253 mmol), and DMSO (2.5 mL) stirring at 100° C. for 2. Purification by sequential column chromatography (silica gel: 0.5 to 10% MeOH/DCM) and reverse phase chromatography (Phenomenex Gemini column, 10 micron, C18, 100 Å, 150×30 mm, 0.1% TFA in ACN/H2O, gradient 5% to 95%) provided tert-butyl (3S)-3-((3-methyl-8-(4-oxo-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl)-2-quinoxalinyl)amino)-1-piperidinecarboxylate (5.2 mg, 4.3%) as the free base after washing with saturated aq. NaHCO3, extracting with 10% MeOH/DCM, drying over Na2SO4, and concentrating under reduced pressure. 1H NMR (CDCl3) δ: 7.92-7.97 (m, 1H), 7.65-7.71 (m, 1H), 7.37-7.45 (m, 1H), 7.13 (s, 2H), 5.42 (br. s., 1H), 4.12 (s, 1H), 3.62-3.70 (m, 3H), 2.91-2.99 (m, 2H), 2.57 (s, 3H), 1.94-2.07 (m, 1H), 1.89-1.90 (m, 1H), 1.80-1.91 (m, 1H), 1.68 (s, 9H), 1.33-1.55 (m, 5H). m/z (ESI, +ve) 477.2 (M+H)+.

1. customPrepared
2. customPurification by sequential column chromatography (silica gel: 0.5 to 10% MeOH/DCM)